A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH [human parathyroid hormone] (1-34) in Comparison to Subcutaneous Injection of Forteo [teriparatide] in Postmenopausal Women With Osteoporosis and Osteopenia [bone resorption].

Trial Profile

A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH [human parathyroid hormone] (1-34) in Comparison to Subcutaneous Injection of Forteo [teriparatide] in Postmenopausal Women With Osteoporosis and Osteopenia [bone resorption].

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Teriparatide; Teriparatide
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2010 Results presented at 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 01 Sep 2009 Primary endpoint 'change from baseline in procollagen 1 N-terminal propeptide (P1NP) levels at 96 days' has been met, as reported in a TransPharma Medical media release. Secondary efficacy and safety endpoints were also met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top